The mission of market access units becomes increasingly important for the success of a new medicine.
We come in on two occasions:
When our clients' reasoning in health-technology assessments (HTA) is to be crosschecked from the point of view of routine clinical care and from the vantage point of opinion leaders. This crosscheck takes place in an Advisoryboard exclusively focused on HTA topics. The rationale of this crosscheck is to maximise HTA performance.
When market access of a new medicine hinges on the successful implementation of a companion diagnostic within a healthcare system / country. We explore the necessary stakeholders, their current procedures, and how the companion diagnostic can be implemented. The implementation is then driven forward in interdisciplinary advisory boards.
Contact us for a confidential and free briefing & proposal. We will set you up with the appropriate WILLWATER men/women for your market access topic / market. Contact.